chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Little pressure in my chest; Pressure in my eyes; Sweats,Perspiration; Anxiety; Really wired; Difficulty Sleeping; Chills; Hot flashes; Diarrhea; This spontaneous case was reported by a patient and describes the occurrence of DIARRHOEA (Diarrhea), HOT FLUSH (Hot flashes), CHEST DISCOMFORT (Little pressure in my chest), OCULAR DISCOMFORT (Pressure in my eyes) and HYPERHIDROSIS (Sweats,Perspiration) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 03-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Sep-2021, the patient experienced DIARRHOEA (Diarrhea). On 05-Sep-2021, the patient experienced HOT FLUSH (Hot flashes), OCULAR DISCOMFORT (Pressure in my eyes), HYPERHIDROSIS (Sweats,Perspiration), ANXIETY (Anxiety), FEELING ABNORMAL (Really wired), INSOMNIA (Difficulty Sleeping) and CHILLS (Chills). On 08-Sep-2021, the patient experienced CHEST DISCOMFORT (Little pressure in my chest). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1 dosage form. On 08-Sep-2021, HOT FLUSH (Hot flashes) had resolved. At the time of the report, DIARRHOEA (Diarrhea), CHEST DISCOMFORT (Little pressure in my chest), OCULAR DISCOMFORT (Pressure in my eyes), HYPERHIDROSIS (Sweats,Perspiration), ANXIETY (Anxiety), FEELING ABNORMAL (Really wired), INSOMNIA (Difficulty Sleeping) and CHILLS (Chills) outcome was unknown.            No Concomitant medications was provided.   Reporter did not allow further contact
Huge bruise on his arm/giant bruise on his whole bicep; Muscle knot; This is a spontaneous report from a contactable consumer or other non healthcare professional. A male patient of an unspecified age received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration on 29May2021 (Batch/Lot Number: EW0187; Expiration Date: 31Aug2021) as 2ND DOSE, SINGLE for covid-19 immunization. Historical vaccination included the patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on 29May2021 (Batch/Lot Number: EW0173; Expiration Date: 31Aug2021) as Single for covid-19 immunization. The patient medical history was not reported.     The patient's concomitant medications were not reported.  The patient experienced huge bruise on his arm/giant bruise on his whole bicep and muscle knot on an unspecified date.Outcome of the events was unknown.  No follow-up attempts are possible. No further information is exected.
Pt came in today 12/14/2021 and said she received a shot in Sept and that her arm is very sore. She originally spoke with  someone else because I was on the phone. As soon as I was off the phone I spoke with her. She claims that her arm is still very sore and that when she tries to lift her arm that its very difficult and that sometimes she cries from the pain.
Pediarix and Infanrix instead of Dtap-IPV; Pediarix and Infanrix on the same day; This case was reported by a physician via call center representative and described the occurrence of wrong vaccine administered in a 5-year-old female patient who received DTPa (Infanrix) (batch number 7EC55, expiry date 29th April 2023) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa-HBV-IPV (Pediarix) (batch number X9HS4, expiry date 25th March 2024) for prophylaxis and dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 4th August 2022, the patient received Infanrix, Infanrix Pre-Filled Syringe Device, Pediarix and Pediarix Pre-Filled Syringe Device. On 4th August 2022, unknown after receiving Infanrix, Infanrix Pre-Filled Syringe Device, Pediarix and Pediarix Pre-Filled Syringe Device, the patient experienced wrong vaccine administered and overdose. On an unknown date, the outcome of the wrong vaccine administered and overdose were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 05-AUG-2022 Reporter's comments: The physician stated that yesterday (from the day of reporting), a 5 years old patient received Pediarix and Infanrix on the same day. The patient was supposed to get 1 Dtap but got 2 (patient should had received Dtap-IPV, MMR, Varivax). The reporter consented to follow-up via postal. Additional supportive information: The patient received Pediarix and Infanrix on the same day. The patient was supposed to get 1 Dtap but got 2 which led to wrong vaccine administered and overdose.
other people who got their Moderna Covid-19 Vaccine and  experiencing  the same  symptoms of  fatigue; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (other people who got their Moderna Covid-19 Vaccine and  experiencing  the same  symptoms of  fatigue) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FATIGUE (other people who got their Moderna Covid-19 Vaccine and  experiencing  the same  symptoms of  fatigue). At the time of the report, FATIGUE (other people who got their Moderna Covid-19 Vaccine and  experiencing  the same  symptoms of  fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment information was provided.
Started having the same problems I had after the 1st dose; Within hours after vaccine started getting arm pain, sweating; started feely achy and began urinating blood; For the next 2 days I stayed in bed and had a fever, chills and lower back pain where my kidneys are; Also started to have a ringing in my ears; After first day in bed I started having severe joint pain, it got progressively worse with time; I couldn't close my hand all the way, not able to hold onto anything; The joint pain slowly got a little better; Returned to work, though ringing in my ears never subsided; The next month I got a really heavy period for 2 weeks.
This spontaneous report as received from a physician's assistant refers to a 19 year old female patient. The patient had non allergies or drug reactions in medical history. In approximately 2015 (reported as about year ago), the patient was vaccinated with her first dose of GARDASIL 9 (dose, frequency and route of administration were not reported, lot/expiration date unknown). Concomitant therapy was not reported. On an unknown date, 1 month after vaccination, the patient developed granulomas of the lungs. The physician's assistant stated patient did not report any treatment for the granulomas and still had them (also reported as adverse event improved). Causality assessment was not reported. Additional information has been requested.
Around 10pm I started to feel weird.  I woke up very ill (fatigue, headache, nausea, weakness, chills).  I had the worst headache and my eyes were hurting for over 24 hours.  My chills turned into a high fever on the night of the 24th and I had a high fever, sweating and vivid, strange dreams that night.  I continued to feel sick until Saturday August 29th with my symptoms diminishing a bit each day.
Recieved the vaccine at 4:30pm; at 4:40, injection site became very itchy; Associate was advised to take Benedryl p.o.; discharged home.  No signs of visible distress following administration and prior to discharge
sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications or treatment details reported.    This case was linked to MOD-2021-035979 (Patient Link).   Reporter did not allow further contact
injection site stinging; This case was reported by a consumer via call center representative and described the occurrence of injection site stinging in a 76-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 7th February 2020, the patient received the 1st dose of Shingrix. On 7th February 2020, less than a day after receiving Shingrix, the patient experienced injection site stinging. On an unknown date, the outcome of the injection site stinging was not recovered/not resolved.   It was unknown if the reporter considered the injection site stinging to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported, but it could be 75 or 76 years. The patient reported injection site stinging with the 1st dose. For tolerance after 2nd dose of Shingrix, refer case US2020185507.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020185507:same reporter
A non-serious report of "head is pounding sinus headache" has been received from a consumer concerning a 45 year-old female.  No medical history nor concomitant medications were provided.  The patient received FLUMIST on 18-Nov-2008.  Two hours after the dose of FLUMIST, the patient report "head was pounding; feels like a sinus headache that is extreme."  The patient was vaccinated at Air force base.  Outcome for the events was not resolved.
Swelling, redness to (L) arm with know at site of injection. Treated with KEFLEX (antibiotic) 500 mg 1 three times daily x 7 days,
Patient reported burning sensation to complete body immediately after obtaining 1st COVID vaccine. Patient A&O x 4, transferred to building via wheelchair. Patient's vitals were taken and patient was evaluated by provider. Patient reports symptoms improving and patient was discharged home.
This case was reported in a literature article and described the occurrence of acute glomerulonephritis in a subject who received Meningococcal ACWY-CRM vaccine. The subject's past medical history included streptococcal infection. On an unknown date, 1 day after receiving Meningococcal ACWY-CRM vaccine, the subject developed acute glomerulonephritis. Serious criteria included GSK medically significant. The outcome of acute glomerulonephritis was unknown. It was unknown if the investigator considered the acute glomerulonephritis to be related to Meningococcal ACWY-CRM vaccine. Additional information was provided. This case was reported in a literature article and described the occurrence of acute glomerulonephritis in a patient aged between 11 and 21 year of unspecified gender who was vaccinated with MENVEO (GlaxoSmithKline). The patient was part of a self-controlled post licensure safety that evaluated the safety profile of quadrivalent meningococcal conjugate vaccine in a large cohort aged 11 to 21 years. The patient had a history of recurrent streptococcal infection. The patient belonged to the risk window. [In this study, the risk window was 1-42 days: time period in which it was hypothesized that the risk of events might be affected by vaccination-following index vaccination (first dose of vaccination)]. No information on patient's family history or concurrent condition or concomitant medication was provided. On an unspecified date between 30 September 2011 and 30 June 2013, the patient received MENVEO (administration route and site unknown; dosages unknown; batch number not provided) at a participating medical centre. On an unspecified date between 1 and 42 days post index vaccination, the patient had acute glomerulonephritis. Treatment was unknown. The outcome of the event was not reported. The authors did not comment on the relationship between the event of acute glomerulonephritis and MENVEO. However, the authors commented that "the patient may have had pre-existing disease, but this cannot be confirmed because no urinalysis tests were available before vaccination". The authors concluded that "This observational study was not intended to provide conclusive evidence of causality. Rather, it detected potential temporal associations between MenACWY-CRM vaccination and adverse events. With nearly 50,000 individuals vaccinated with MenACWY-CRM included in this study, we observed a temporal association between occurrence of Bells' palsy and receipt of MenACWY-CRM concomitantly with other vaccines. The association needs further investigation because it could be due to chance, concomitant vaccination, or underlying medical history predisposing to Bells' palsy". This is 1 of the 8 valid cases reported in the same literature article.
red rash starting below breasts and spreading to neck and back which lasted for three days.  Took Benadryl for two days. rash is faded but still remains
Vaccination administered in left deltoid.  Left axillary pain and fever one day following vaccination.  Large bruise developed one day later.  Left forearm and hand tingling associated with grip deficiency developed one day later.  12 cm. by 13 cm. area of ecchymosis ultimately noted.  Suspected left brachial radiculopathy treated with gabapentin.
patient tested positive for COVID on 9/2/21  ED MD note: 66-year-old female with past medical history of COPD presenting for shortness of breath and cough.  Patient says for the past week she has increased cough productive of green and yellow sputum.  Denies any fever or chills.  She is also having a sore throat causing her to eat and drink less than usual.  In April, she did get the Johnson & Johnson COVID-19 vaccination.  She has been using her inhaler, but is out of her nebulizer treatment.  She also states that she did recently travel up to Connecticut in the past week.  She is having some chest tightness, but no pain
Initial report received on 05 November 2013 from a health care professional  3 patients whose age, gender, medical history and concomitant medications were not reported, received a dose of FLUZONE HD (lot number U4765AA, expiration date unknown and site of vaccination was unknown) administered intramuscularly in 2013. It was reported that 3 patients have received the FLUZONE HD. In 2013, 3 patients reported significant injection site reaction 7-8 cm of swelling, redness and warm to touch. List of documents held by sender: none
blisters; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date Mar2021 at 02:30 pm (Lot number: EP 7533) at the age of 62 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BLISTER (non-serious) with onset 2021, outcome "unknown", described as "blisters".  Additional information: No other vaccine in four weeks. No treatment AE. No known allergies. No COVID prior vaccination. No COVID tested post vaccination.  No follow-up attempts are possible. No further information is expected.
Describe Event, Problem, or Product Use Error: [Pfizer booster] use for COVID-19 under Emergency Use Authorization (EUA):Gave an employee a Covid 19 Pfizer Booster that was expired by 10 hours. Manager contacted Pfizer and per Pfizer was considered safe to patient-no action needed.
Light Rash Around the Injection Site; Left Arm; light redness around the injection site; arm was very sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 04Mar2021 (Lot number: EN6205) at the age of 72 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: VACCINATION SITE RASH (non-serious) with onset 17Mar2021 10:30, outcome "unknown", described as "Light Rash Around the Injection Site; Left Arm"; PAIN IN EXTREMITY (non-serious) with onset 04Mar2021, outcome "recovered" (06Mar2021), described as "arm was very sore"; VACCINATION SITE ERYTHEMA (non-serious) with onset 17Mar2021, outcome "unknown", described as "light redness around the injection site". Therapeutic measures were taken as a result of vaccination site rash, pain in extremity, vaccination site erythema. Additional information: The patient had no prior vaccinations (within 4 weeks). The treatment received was Tylenol.  No follow-up attempts are possible. No further information is expected.
Chest pain/chest wall pain two days after booster shot. EKG and blood work to check for heart issue and blood clots.
This spontaneous report was received from a healthcare worker refers to a patient of unknown demographics. No relevant medical history was reported. On 15-JAN-2014, the patient was vaccinated with ZOSTAVAX (lot number 0069AE and expiry date 03-APR-2013) (dose and route not specified). On an unknown date, an unspecified patient received an expired dose of ZOSTAVAX. No adverse effect has been reported. Additional information has been requested.
11/10/2021 (at midnight): SOB, chest congestion/tightness, increased pulse, decreased oxygen saturation and increased respiration rate.
Adverse reaction or side effect: N/A; PNEUMOVAX administered on 24-APR-2011, 30-NOV-2015 and 01-DEC-2016; This spontaneous report was received from a lawyer and refers to a 69 year old male patient. The patient's concurrent conditions, concomitant medications and drug allergies/reactions were not reported. The patient had a history of shingles while on prior therapy with zoster live vaccine (ZOSTAVAX) (case #1905USA010000 which was part of a litigation process) and product use for unapproved indication while on therapy with alendronate sodium (FOSAMAX) (case #2012USA000182)  On 26-APR-2011, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) for prophylaxis (dose, dose number, route, anatomical site of vaccination, lot number and expiration date were not reported. The patient also received additional doses of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) on 30-NOV-2015 and 01-DEC-2016 (inappropriate schedule of product administration).  The patient did not experience adverse reaction or side effects with the vaccine.; Sender's Comments:  US-009507513-1905USA010000: US-009507513-2012USA000182:
6/24/2022-Presents to ED, + home covid test and coughing. Covid + test. ABG-7.46/34.1/32/24.4. CT chest bibasilar mild consolidation and minimal plueral effusions. 2L NC 96%.HR-113.  Ordered dexamthasone, CAP coverage IV azithromycin , Rocephin and Remdesivir. Intial bp was 76/45 bolus given, now 89/50, patients baseline. MAP is around 63-65, started on levophed and fluids were d/c questionable HF. WBC 3.1 was 6.1 6 days prior, leukopenia immunotherapy in the setting of multiple myeloma. D Dimer 1125, CT was negative for PE. Admit acute hypoxic rep distress s/t to Covid pna.  6/26/2022- D/C remdesivir, no longer hypoxic. VSS. WBC 4.3. 6/28/2022-Continues on RA for 02, completed IV azithromycin and Rocephin course. VSS. D/CLevophed map around 70's. D/C Home.
Redness; Itching; myalgia; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA, PRURITUS, and ERYTHEMA in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Oct-2021, the patient experienced MYALGIA. On 28-Oct-2021, the patient experienced PRURITUS. On 30-Oct-2021, the patient experienced ERYTHEMA. On 20-Oct-2021, MYALGIA outcome was unknown. On 29-Oct-2021, PRURITUS had resolved. At the time of the report, ERYTHEMA outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  Concomitant medication was not reported. Treatment information was not reported.
Child had three (3) hives (dime to penny size) red with white center 30 minutes after vaccinations given.  One on his right leg and one on each buttock.  No other S/S and they were gone by 2:30 to 2:50pm the same day.  Mom thought he had a low-grade fever, but she did not check his temperature. Follow-up telephone call the next morning - mom said he was fine, acting normal.
I always need to rest for a couple of days after receiving the vaccine. My lymph nodes swelled under my left for about six weeks after receiving the vaccine. I tested positive for COVID-19 in 03/2023. I did not contact my doctor immediately and I just took over the counter medication to help with my symptoms. My chief complaint was not being able to breath, and I had a bad headache. I do have history of asthma, so I used my inhaler more often than normal. As of today, I am able to breath better.
Tdap given inappropriately - previous had dose of Tdap 7/22/10 (historical dose). Patient stsated needed Tdap, was given missed seeing she had already had dose. Patient was notified.
Also listed on form is Fluzone High Dose 65+ Lot # UJ750AC  Exp June 30,2022 however the first listed above is circled on my form
Redness and swelling at injection site, began approx. 5 mins after injection. Parent advised to remain in clinic for 15 minutes to observe patient. No difficulty breathing. Sx began to resolve. Advised parent to monitor and call 911 or go to ER if s/sx worsened or any difficulty breathing or lethargy. Advised cold compress and children's Tylenol as needed.
Got my vaccine early morning.  Left arm where injection site given,  started to become really sore 30 minutes after injection.  I ate breakfast at around 9:30am. Went to my Doctor's appointment for 1030am, started having mild chills that would come and go. After Doctor's appointment,  around 1130-12pm, started to feel nauseous and loss of thirst and appetite.  I called the vaccine line at my job at around 2:59pm, but nurse just stated nothing to do right now, to call back following morning.  I knew things would get worse so I made the judgement call to call out this was close to 4pm. My chills started increasing,  despite not having any high temp was 98.9 f. Then around 5pm started having mild joint pain all over my body. Around 7pm joint pain got unbearable,  that I even started to shiver from more chills and pain.  I couldn't sleep,  except just laying and tossing and turning in bed, I also started having stomach cramping . Finally I fell asleep at around 12:30 midnight,  due to the pain. I finally woke up around 3:30am, took 2 Motrins. Then I woke up around 06:30am with body aches all over. Last night just took sips of ginger ale, didn't eat anything since 9:30am yesterday.  Finally had a small breakfast at around 7:30am with a glass of water. Still feel warm at times, with body aches, and nausea.  Will call vaccine line again today.